The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
 
Caleb Joshua Smith
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Diane M. Simeone
Consulting or Advisory Role - FibroGen
Research Funding - Biological Dynamics; Clearnote Health; Immunovia; Micronoma
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
 
Patrick Grierson
Employment - Walgreens (I)
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Pancreatic Cancer
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Seagen; Veru
Consulting or Advisory Role - MyCareGorithm
Travel, Accommodations, Expenses - A2Bio
 
Maria Pia Morelli
No Relationships to Disclose
 
Sandip Pravin Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
Matthew L. Ulrickson
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb; Genentech; Gilead Sciences; Stemline Therapeutics
Travel, Accommodations, Expenses - Miltenyi Biomedicine
Other Relationship - Safety Review Committee: Kura Oncology
 
Saurabh Dahiya
Consulting or Advisory Role - Kite, a Gilead Company
 
Jong Chul Park
Consulting or Advisory Role - GC Cell (I)
Research Funding - A2 Biotherapeutics; Alentis Therapeutics; ALX Oncology; Ankyra Therapeutics; InhibRx
 
Jennifer M. Specht
Honoraria - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline; Sensei Biotherapeutics
Consulting or Advisory Role - Daiichi Sankyo; GE Healthcare; GlaxoSmithKline; Lyell Immunopharma Inc; Sensei Biotherapeutics; Volastra Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Carisma Therapeutics (Inst); Cascadian Therapeutics (Inst); Celcuity (Inst); Genentech (Inst); Lyell Immunopharma (Inst); Merck (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - UW CoMotion - Patent Royalty for ROR1 CAR (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; GE Healthcare; GlaxoSmithKline; Nektar
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Kirstin B. Liechty
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; Ceria Therapeutics
 
Jessica Tebbets
Employment - A2 Biotherapeutics
 
John Sutton Welch
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen Oncology (Inst); Notable Labs (Inst)
 
William Y. Go
Employment - A2 Biotherapeutics
Leadership - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen; Gilead Sciences
Other Relationship - American Psychiatric Association Foundation; Viewpoint School
 
David G. Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics; NAVAN Technologies
Honoraria - Bristol-Myers Squibb; Caribou Biosciences; Celgene; Genentech; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead Company; Lilly; MustangBio; Novartis; Umoja Biopharma
Consulting or Advisory Role - BMS, Member of the JCAR017 EAP-001 Safety Rev; Genentech, Member and Chair of the Lymphoma Steering Committee
Research Funding - Bristol-Myers Squibb; Celgene; Juno Therapeutics; Kite, a Gilead Company; Legend Biotech
Patents, Royalties, Other Intellectual Property - Rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS (Inst)
(OPTIONAL) Uncompensated Relationships - BMS, Member of the JCAR017-BCM-03 Scientific Steering Committee
 
Marcela Valderrama Maus
Leadership - 2Seventy Bio Board of directors
Stock and Other Ownership Interests - 2seventy bio; Century Therapeutics; Genocea Biosciences; NexImmune; Oncternal Therapeutics; TCR2 Therapeutics
Honoraria - ArsenalBio
Consulting or Advisory Role - Adaptimmune; Agenus; Allogene Therapeutics; Arcellx; Astellas Pharma; AstraZeneca; Atara Biotherapeutics; Bayer; Bristol-Myers Squibb; Cabaletta Bio (SAB); Cellectis (SAB); Crispr Therapeutics; Genocea Biosciences; GlaxoSmithKline; In8bio (SAB); Intellia Therapeutics; Kite, a Gilead Company; Micromedicine/BendBio; NexImmune; Novartis; Oncternal Therapeutics; Sanofi; TCR2 (SAB); Tmunity Therapeutics, Inc.; WindMIL (SAB)
Research Funding - Kite, a Gilead Company; Novartis
Patents, Royalties, Other Intellectual Property - Multiple, owned by Massachusetts General Hospital (Inst); Novartis; Promab
Expert Testimony - Australia FPA
 
Eric Wai-Choi Ng
Employment - A2 Biotherapeutics; Amgen
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen
Travel, Accommodations, Expenses - A2 Biotherapeutics; Amgen
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - A2 Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Camurus (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen